Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response…
OSE Immunotherapeutics Publishes Letter to Shareholders
OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00…
Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025
ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories,…
